» Articles » PMID: 24494676

Neurotrophins, Endocannabinoids and Thermo-transient Receptor Potential: a Threesome in Pain Signalling

Overview
Journal Eur J Neurosci
Specialty Neurology
Date 2014 Feb 6
PMID 24494676
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Because of the social and economic costs of chronic pain, there is a growing interest in unveiling the cellular and molecular mechanisms underlying it with the aim of developing more effective medications. Pain signalling is a multicomponent process that involves the peripheral and central nervous systems. At the periphery, nociceptor sensitisation by pro-inflammatory mediators is a primary step in pain transduction. Although pain is multifactorial at cellular and molecular levels, it is widely accepted that neurotrophin (TrkA, p75NTR, Ret and GFRs), cannabinoid (CB1 and CB2), and thermo-transient receptor potential (TRPs; TRPV1, TRPA1 and TRPM8) receptors play a pivotal role. They form a threesome for which endocannabinoids appear to be a first line of defence against pain, while neurotrophins and thermoTRPs are the major generators of painful signals. However, endocannabinoids may exhibit nociceptive activity while some neurotrophins may display anti-nociception. Accordingly, a clear-cut knowledge of the modulation and context-dependent function of these signalling cascades, along with the molecular and dynamic details of their crosstalk, is critical for understanding and controlling pain transduction. Here, the recent progress in this fascinating topic, as well as the tantalizing questions that remain unanswered, will be discussed. Furthermore, we will underline the need for using a systems biology approach (referred to as systems pain) to uncover the dynamics and interplay of these intricate signalling cascades, taking into consideration the molecular complexity and cellular heterogeneity of nociceptor populations. Nonetheless, the available information confirms that pharmacological modulation of this signalling triad is a highly valuable therapeutic strategy for effectively treating pain syndromes.

Citing Articles

Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.

Henson J, Vitetta L, Hall S Inflammopharmacology. 2022; 30(4):1167-1178.

PMID: 35796920 PMC: 9294022. DOI: 10.1007/s10787-022-01020-z.


Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain.

Fitzcharles M, Petzke F, Tolle T, Hauser W Drugs. 2021; 81(18):2103-2116.

PMID: 34800285 DOI: 10.1007/s40265-021-01602-1.


Evaluation of the analgesic potential and safety of chvar. essential oil.

Xiao S, Yu H, Xie Y, Guo Y, Fan J, Yao W Bioengineered. 2021; 12(2):9860-9871.

PMID: 34699310 PMC: 8810075. DOI: 10.1080/21655979.2021.1996149.


A capsaicinoid-based soft drug, AG1529, for attenuating TRPV1-mediated histaminergic and inflammatory sensory neuron excitability.

Nikolaeva-Koleva M, Butron L, Gonzalez-Rodriguez S, Devesa I, Valente P, Serafini M Sci Rep. 2021; 11(1):246.

PMID: 33420359 PMC: 7794549. DOI: 10.1038/s41598-020-80725-z.


Roles of tumor necrosis factor-α and interleukin-6 in regulating bone cancer pain via TRPA1 signal pathway and beneficial effects of inhibition of neuro-inflammation and TRPA1.

Zhao D, Han D, Wang S, Lv B, Wang X, Ma C Mol Pain. 2019; 15:1744806919857981.

PMID: 31144562 PMC: 6580714. DOI: 10.1177/1744806919857981.